Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReNeu: Mirdametinib in NF1-Associated Plexiform Neurofibromas
NCT03962543Phase 2Active, not recruiting
- Sponsor
- SpringWorks Therapeutics
- Start
- Sep 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mirdametinib in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN), sponsored by SpringWorks Therapeutics. Primary endpoint: Objective Response Rate at 24 months. Started Sep 2019; status: active, not recruiting.
02
Drugs
mirdametinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT03962543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03962543.